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proposed supervised injection facilities in
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Ehsan Jozaghi*, Andrew A Reid and Martin A AndresenAbstract
Background: This paper will determine whether expanding Insite (North America’s first and only supervised
injection facility) to more locations in Canada such as Montreal, cost less than the health care consequences of not
having such expanded programs for injection drug users.
Methods: By analyzing secondary data gathered in 2012, this paper relies on mathematical models to estimate the
number of new HIV and Hepatitis C (HCV) infections prevented as a result of additional SIF locations in Montreal.
Results: With very conservative estimates, it is predicted that the addition of each supervised injection facility (up-to a
maximum of three) in Montreal will on average prevent 11 cases of HIV and 65 cases of HCV each year. As a result,
there is a net cost saving of CDN$0.686 million (HIV) and CDN$0.8 million (HCV) for each additional supervised injection
site each year. This translates into a net average benefit-cost ratio of 1.21: 1 for both HIV and HCV.
Conclusions: Funding supervised injection facilities in Montreal appears to be an efficient and effective use of financial
resources in the public health domain.
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The spread of infectious diseases among injection drug
users (IDUs) is a serious public health concern. In a re-
cent systematic review and meta-analysis analyzing
research studies from Western Europe, Asia, Latin
America, Australasia, Eastern Europe, and North
America it was found that acquired immunodeficiency
syndrome (AIDS) and a number of other blood-borne
diseases transmitted through shared needles and syrin-
ges are of the leading causes of death across 67 cohorts
of IDUs [1]. The extent of these health concerns is par-
ticularly troubling. The World Health Organization
notes that globally approximately 16 million people in-
ject drugs and of those 3 million are living with the hu-
man immunodeficiency virus (HIV) [2]. While rates of
injection drug use and the contraction of infectious dis-
eases may be elevated in certain regions of the world,* Correspondence: eja2@sfu.ca
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problems.
In Canada, for example, based on the most recent data
available there were 1695 deaths attributable to illegal
drug use in 2002 [3]. AIDS is a significant cause of death
related to illicit drugs, with 87 identified AIDS deaths at-
tributed to injection drug use in that year [3]. Further, ap-
proximately 70 percent of new hepatitis C virus (HCV)
infections in Canada are attributable to injection drug use
and needle sharing [4]. The spread of infectious diseases is
not, however, the only concern.
These problems are of particular concern in Canada’s
urban areas where IDU populations are large. In Montreal,
Quebec for example, the IDU population has been esti-
mated at between 4,300 and 12,500 individuals [5]. This
elevated IDU population translates into increased infec-
tion rates. In fact, HIV and HCV prevalence rates for IDUs
in Montreal have been estimated to be as high as 18 per-
cent and 68 percent, respectively [6]. Despite having vari-
ous harm reduction strategies implemented in the greater
Montreal area (such as 11 needle depots, 11 communityl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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that distribute approximately 800,000 syringes), IDUs con-
tinue to share their injection drug equipment [7,8]. Recent
data from Montreal indicates rising incidents of HIV and
HCV among IDUs from 2004 to 2006 [9,10].
Recognizing these growing concerns, the Quebec gov-
ernment has shown interest in adopting further strategies
to reduce the spread of infectious diseases in its IDU
population. One such strategy is a supervised injection
facility such as Insite that has been in operation in
Vancouver, British Columbia since 2003—North America’s
first and only legal supervised injection facility. Though its
continued operation has faced legal obstacles, in a recent
Supreme Court of Canada case the continuation of Insite’s
operation was upheld (PHS Community Services v. Attor-
ney General of Canada, BCSC, 2008; Canada [Attorney
General] vs PHS Community Services Society, 2011 SCC
44). Buoyed by this most recent Supreme Court of Canada
ruling, and in order to reduce the public health and fiscal
impacts of injection drug use, the Quebec government has
shown interest in opening supervised injection facilities
(SIFs) in Montreal [11]. According to Quebec’s Health and
Social Services Minister, Yves Bolduc, SIFs “will offer ser-
vices that will monitor the health of drug addicts and en-
courage them to seek detoxification and rehabilitation”
[10]. Health officials in the City of Montreal have already
proposed three SIFs plus a mobile SIF that will attempt to
reach the IDU population [10]. At this point, however, it is
unclear exactly what magnitude of impact the proposed
SIFs may have for the City of Montreal. An obvious ques-
tion that is of great concern to City officials is: Are SIFs an
efficient and effective use of financial resources? This issue
is of critical importance because of the recently established
more restrictive rules made by the Federal government in
order to establish a supervised injection facility [12,13].
The current paper presents cost-effectiveness and
cost-benefit analyses for various SIF operation scenarios
in Montreal in an effort to inform public policy on this
complex issue. Specifically, the analyses estimate the
number of new HIV and HCV infections prevented as a
result of operating SIFs using mathematical modelling
with conservative parameter estimates. The dollar costs
of illnesses avoided are compared to the operational cost
of a SIF. The analyses are then extended to consider the
impact of opening additional SIFs. As long as the mar-
ginal benefits outweigh the marginal costs of additional
SIFs hours and locations, the expansion of SIF should be
recommended. At some point, however, it is expected
that the marginal cost of expansion will exceed the mar-
ginal benefits.
Related studies
Due to inherent issues associated with the legality of in-
jection drug use in many countries around the world,few SIFs have been put into practice [14]. Consequently,
research examining the cost-benefit and cost-effectiveness
characteristics of SIFs is very limited [13]. The first pub-
lished economic analysis of the SIF portion of Insite con-
sidered a complex dynamic compartmental simulation
model for the City of Vancouver as a whole and projected
new HIV and hepatitis C infections over a 10-year time
horizon with and without Insite [15]. In their baseline
model, the authors estimated 1191 new HIV and 54 new
hepatitis C cases were averted, a simple average over the
10 years of 120 new cases of HIV each year. Considering
the lifetime cost of a new HIV infection at $210 555 [16],
these averted cases led to an annual savings of $25 million,
and a benefit-cost ratio of 16.84, assuming a $1.5 million
cost of operations for the SIF portion of Insite [17].
Therefore, this model predicted that Insite prevented 80
percent of all new IDU cases of HIV each year for all of
British Columbia when approximately 5 percent of all in-
jections in Vancouver’s DTES took place within Insite.
This model is complex, dynamic, and considers a score of
variables, but the results are quite simply not believable.
Another economic costing study showed that Insite as a
whole (SIF, needle exchange program, etc.) was extremely
cost-effective, but the SIF alone contributed very little:
83.5 new HIV cases were averted each year, with 2.8 attrib-
uted to the SIF [16]. Considering the values used above,
this led to a benefit-cost ratio of 0.37. Clearly, these latter
results indicate that Insite should not continue its SIF ac-
tivities if costs are to determine that choice.
Using a mathematical modeling approach, a cost-benefit
and cost-effectiveness analysis of Insite was also under-
taken that resulted in much more believable results [17].
These researchers considered 4 mathematical models used
in the needle exchange evaluation literature, varying par-
ameter values in a sensitivity analysis, and found that 19
to 57 new cases of HIV are averted, an average of 35 cases
averted each year. This led to benefit-cost ratios ranging
from 1.94 to 5.8, an average of 3.56.
Most recently, researchers conducted a costing study to
determine if an expansion of the SIF program could im-
prove upon the cost-benefit and cost-effectiveness estimates
found in the earlier research [13]. The study also explored
the degree to which the services could be expanded before
diminishing returns would take effect. The analyses demon-
strated that while expanding Insite may lead to further cost
savings, this result was dependant on behavioral changes in
the IDU population [13]. In other words, Insite would have
to recruit new users from the IDU population in order for
additional cost-savings to be achieved.
An obvious question emerges at this point in the discus-
sion: why do one set of results [16] differ so much from
the other studies [13,15,17]? The answer is simple. The re-
search that did not support the SIF portion of Insite [16]
did not consider behavioral changes of IDUs with regard
Table 1 Sources for variables used in mathematical modeling
Variable Value Source
Proportion of IDUs HIV- (I) 81.20% Généreux et al. [19]; Broadhead, Kerr, Grund & Altice [20]
Rate of Needle sharing (s) 35% Bruneau et al. [9]; De et al. [8]; Généreux et al. [19]
Number of needles in circulation (N) 800000 Morissette et al. [7]
Percentage of needles not cleaned (d) 17.00% Jacobs et al. [18]; Kaplan and O'Keefe [21]
Probability of HIV infections from a single injection (t) 0.67% Kaplan and O'Keefe [21]
Number of sharing partners (m) 1.38 Jacobs et al. [18]
Proportion of IDUs HIV+ (q) 18.80% Broadhead et al. [20]; Généreux et al. [19]
Proportion IDUs HCV- (I) 30.00% De et al. [8]; Broadhead et al. [20]; Généreux et al. [19]
Proportion of IDUs HCV+ (q) 70.00% De et al. [8]; Broadhead et al. [20]; Généreux et al. [19]
Probability of HCV infection from single injection (t) 3% Gore & Bird [22]
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cated that Insite was cost-saving for society, but for different
reasons: the SIF [13,15,17] and the needle exchange pro-
gram [16]. Because the SIF within Insite is the contentious
aspect of Insite, we focus our analysis on the SIF. We con-
sider this reasonable because these two functions of Insite
are separable and distinguishable. And because of the em-
pirical support for changes in the behaviour of IDUs [17]
and the realistic nature of the simple mathematical model-
ing approach [13,17], we follow the methodology of these
researchers.
While most of the studies related to Insite found positive
cost-benefit and cost-effective results when considering the
Vancouver-based SIF, it would be irresponsible to assume
that the same benefits would be experienced for the imple-
mentation of SIFs in other geographic locations. As a result,
with increasing interest in adopting SIFs in the Montreal
area, cost-benefit and cost-effectiveness analyses in that
specific location are warranted.
Methods
Model
For the purposes of the current analysis, it was necessary to
rely on a model that could reflect the effects of providingTable 2 The cumulative annual cost saving, cost - effectivene
et al. [18] model
Variables Annual cost
of operation
Sharing
rate
# of HIV
averted
# of HCV
averted
HIV cost
saved
HCV c
save
Post SIF $2,182,800 35% 14 84 $764,970 $769,2
Two SIF $4,365,600 28% 26 162 $1,108,830 $1,327
Three SIF $6,548,400 21% 32 195 $189,360 $304,4
Four SIF $8,731,200 18% 37 227 -$940,665 -$753,7
Five SIF $10,914,000 16% 43 261 -$1,860,135 -$1,741
Six SIF $13,096,800 13% 48 294 -$2,990,160 -$2,764
Seven SIF $15,279,600 10% 53 327 -$4,120,185 -$3,787
Average $8,731,200 7% 36 221 -$1,151,220 -$964,5clean injection equipment and adopting safer injecting be-
haviors within its scope of calculation. Drawing from the
methodological approach adopted in recent research on the
economic impact of a needle exchange program in Edmon-
ton, Alberta, Canada [17], the current study uses a math-
ematical model to estimate the number of HIV and HCV
infections that could be prevented through the establish-
ment of a SIF in Montreal [18]. The number of new HIV
infections avoided, (A), is calculated as follows:
A ¼ INsd 1− 1−qtð Þm½ ;
where (I) is the IDU population that is HIV or HCV nega-
tive, (N) is the number of needles in circulation, (s) is the
needle sharing rate, (d) is the percentage of needles not
cleaned before use, (q) is the HIV or HCV prevalence in
the IDU population, (t) is the probability of HIV or HCV
transmission when using an HIV/HCV infected needles,
and (m) is the number of sharing partners when injections
are shared.
Variables and parameters
The values of the variables and parameters identified in the
above equation were derived from Montreal-specificss and cost – benefit of SIF in Montreal using the Jacobs
ost
d
Cost-effectiveness
ratio HCV
Cost-effectiveness
ratio HIV
Cost-benefit
ratio HCV
Cost-benefit
ratio HIV
12 $25,986 $155,914 1.35 1.35
,566 $26,948 $167,908 1.25 1.25
85 $33,582 $204,637 1.03 1.03
39 $38,463 $235,978 0.89 0.89
,677 $41,816 $253,814 0.83 0.83
,758 $44,547 $272,850 0.77 0.77
,839 $46,727 $288,294 0.73 0.73
97 $39,508 $242,533 0.87 0.87
Table 3 The marginal annual cost saving, cost - effectiveness and cost – benefit of SIF in Montreal using the Jacobs
et al. [18] model
Variables Annual cost
of operation
Sharing
rate
Marginal # of
HIV averted
Marginal # of
HCV averted
Marginal Marginal Marginal Marginal Marginal Marginal
HIV cost
saved
HCV cost
saved
cost-
effectiveness
ratio HCV
cost-
effectiveness
ratio HIV
cost-
benefit
ratio HCV
cost-
benefit
ratio HIV
Post SIF $2,182,800 35% 14 84 $764,970 $769,212 $25,986 $155,914 1.35 1.35
Two SIF $2,182,800 28% 12 78 $343,860 $558,354 $27,985 $181,900 1.26 1.16
Three SIF $2,182,800 21% 6 33 -$919,470 -$1,023,081 $66,145 $363,800 0.53 0.57
Four SIF $2,182,800 18% 5 32 -$1,130,025 -$1,058,224 $38,463 $436,560 0.52 0.48
Five SIF $2,182,800 16% 6 34 -$1,200,540 -$987,938 $41,816 $363,800 0.55 0.58
Six SIF $2,182,800 13% 5 33 -$1,130,025 -$1,023,081 $66,145 $436,560 0.53 0.57
Seven SIF $2,182,800 10% 5 33 -$919,470 -$1,023,081 $66,145 $436,560 0.53 0.57
Average $2,182,800 7% 8 47 -$498,360 -$531,079 $46,442 $272,850 0.76 0.77
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specific data were not available, values from the medical
and scientific literature were used as estimates (see Table 1).
When several estimates were available in the medical and
scientific literature, selection preference was given to values
leading to lower bound benefits, making the estimates con-
servative. At its core, the cost-benefit and cost-effectiveness
analysis of this study relied on the number of HIV and
HCV infections prevented. In addition, however, the life-
time costs of treating HIV and HCV infections, the oper-
ational costs of the potential SIFs in Montreal, new HIV
and HCV cases prevented for each additional facility, and fi-
nally, the desirable number of facilities were all required for
complete model specification.
Infectious disease cases prevented
With respect to previous costing studies of SIFs, it has been
demonstrated that it is safe to presume that SIFs are able to
prevent the risk of new HIV cases because there will be a
certain number of known “clean” injections (not shared) as
opposed to “dirty” injections (shared) outside of the facility
[13,16,17]. In line with previous literature then, the current
study employed a point estimate of 0.3 for behavioral
change [13,15,16]. To provide a more conservative estimate,Table 4 The sensitivity analysis at 45% sharing rate for marg
cost – benefit of SIF in Montreal
Variables Annual cost
of operation
Sharing
rate
# of HIV
averted
# of HCV
averted
HIV cost
saved
HCV co
saved
Post SIF $2,182,800 45% 19 115 $1,817,745 $1,858,6
Two SIF $2,182,800 35% 16 99 $1,186,080 $1,296,3
Three SIF $2,182,800 27% 7 43 -$708,915 -$671,6
Four SIF $2,182,800 23% 7 43 -$708,915 -$671,6
Five SIF $2,182,800 20% 7 43 -$708,915 -$671,6
Six SIF $2,182,800 16.00% 7 43 -$708,915 -$671,6
Seven SIF $2,182,800 12% 7 43 -$708,915 -$671,6
Average $2,182,800 9% 10 61 -$540,750 -$203,2an odds ratio of 0.3 was only used for the first and second
potential SIFs in Montreal; this was done to limit the num-
ber of new users of the Montreal SIFs simply because we
cannot expect all IDUs to start using such facilities.
Using the same odds-ration as the Vancouver study that
estimated 20–30 new HIV infections prevented, the math-
ematical model used in the current analysis estimated that
the number of new HIV infections would fall from 67 to 53
with the establishment of the first SIF [23]. This repre-
sented a reduction of 14 new HIV cases per year using the
model [18]. In addition, the model used [18] estimated that
84 new cases of HCV would be averted with the establish-
ment of the first SIF in Montreal. Considering the param-
eter values and the model employed here, the predicted
decline in HCV is from 410 to 326. As with the study of
Vancouver’s SIF, we do not consider the impact of the SIF
on secondary transmissions, such as those through sexual
contact, because reliable data are not available.
The medical cost of New HIV and HCV cases
The range of lifetime cost-savings (in 2012 dollars) from
averted cases of HIV is great, ranging from $174,410 [24],
to US$200,000 [25-27], to more than $289,970 when
considering the very successful HAART program [28].inal annual cost saving, cost - effectiveness and
st Cost-effectiveness
ratio HCV
Cost-effectiveness
ratio HIV
Cost-benefit
ratio HCV
Cost-benefit
ratio HIV
45 $18,980 $114,884 1.85 1.8
57 $22,048 $136,425 1.6 1.5
51 $50,763 $311,829 0.7 0.68
51 $50,763 $311,829 0.7 0.68
51 $50,763 $311,829 0.7 0.68
51 $50,763 $311,829 0.7 0.68
51 $50,763 $311,829 0.7 0.68
53 $42,120 $258,636 1 0.95
Table 5 The sensitivity analysis at 25% sharing rate for marginal annual cost saving, cost - effectiveness and
cost – benefit of SIF in Montreal
Variables Annual cost
of operation
Sharing
rate
# of HIV
averted
# of HCV
averted
HIV cost
saved
HCV cost
saved
Cost-effectiveness
ratio HCV
Cost-effectiveness
ratio HIV
Cost-benefit
ratio HCV
Cost-benefit
ratio HIV
Post SIF $2,182,800 25% 10 64 -$77,250 $66,352 $34,106 $218,280 1.03 1
Two SIF $2,182,800 20% 9 55 -$287,805 -$249,935 $39,687 $242,533 0.89 0.87
Three SIF $2,182,800 15% 4 24 -$1,340,580 -$1,339,368 $90,950 $545,700 0.39 0.39
Four SIF $2,182,800 13% 4 24 -$1,340,580 -$1,339,368 $90,950 $545,700 0.39 0.39
Five SIF $2,182,800 11% 4 24 -$1,340,580 -$1,339,368 $90,950 $545,700 0.39 0.39
Six SIF $2,182,800 9.00% 4 24 -$1,340,580 -$1,339,368 $90,950 $545,700 0.39 0.39
Seven SIF $2,182,800 7% 4 24 -$1,340,580 -$1,339,368 $90,950 $545,700 0.39 0.39
Average $2,182,800 14% 6 34 -$919,470 -$987,938 $64,200 $363,800 0.55 0.58
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savings for HIV infections among IDUs (recognizing
that IDUs may experience certain self-imposed barriers
or other societal limitations making it less likely for an
IDU to take full advantage of the medical system), a
lower bound value of $210, 555 was chosen [29]. This
value is based on the most recent research in this area
[13,16,30].
With respect to costing studies for HCV, the cost-
savings range from $20,000 per completed patient
course of treatment [31], to $30,000 [28], to more than
$69,188 [32]. Once again, here a conservative figure of
$35,143 (2012 Dollars), as reported in [33], was chosen.
New infectious disease cases
Because no other study has calculated the number of
sharing partners in an IDU population, the current
model drew from [18] to obtain a value of 1.38. Further,
although (d)—the percentage of needles not cleaned be-
fore use—was 50 percent in [18], the current analysis
used the more conservative estimate of 17 percent that
was implemented in [21] to make our estimates that
much more conservative. The number of total injec-
tions within Montreal was also unavailable; therefore,
the current study used the product of the number ofTable 6 The sensitivity analysis at 45% sharing rate for cumu
cost – benefit of SIF in Montreal
Variables Annual cost
of operation
Sharing
rate
# of HIV
averted
# of HCV
averted
HIV cost
saved
HCV co
saved
Post SIF $2,182,800 45% 19 115 $1,817,745 $1,858,6
Two SIF $4,365,600 35% 35 214 $3,003,825 $3,155,0
Three SIF $6,548,400 27% 42 256 $2,294,910 $2,448,2
Four SIF $8,731,200 23% 49 299 $1,585,995 $1,776,5
Five SIF $10,914,000 20% 56 341 $877,080 $1,069,7
Six SIF $13,096,800 16.00% 63 384 $168,165 $398,1
Seven SIF $15,279,600 12% 70 427 -$540,750 -$273,5
Average $8,731,200 9% 48 291 $1,375,440 $1,495,4IDUs (4,300) and the number of injections per year
(913) to arrive at a parameter estimate of 3.926 million
injections [18,34-36].
Cost of SIFs
In order to estimate the cost of establishing SIFs, the
analysis must consider the variable and fixed operating
cost of existing SIFs. As a result, the study drew these
parameters from Insite, the only available comparison
facility. The total annual operating cost of Insite in
Vancouver is estimated to be $3 million [13,16,37]. This
$3 million figure includes primary healthcare, peer
counselling, education, housing services, public health
screening (immunisation and diagnostic), addiction
counselling and case management [13,16,37].
The annual operating cost of Insite in terms of property
rental, and supervised injection facility provisions such as
injection kits (e.g., insulin syringes with attached needles,
bottles of sterile water for injection, latex condoms, alco-
hol swaps, cost of disposal of used syringes), staff salaries,
and equipment purchases is estimated to be $1.53 million
[13]. When considering the expansion of Insite from 18 to
24 hours, the operational cost of Insite reaches $2.182 mil-
lion (2012 dollars)–a one-third increase in the hours of
operation [13]. As a result, the current study used $2.182lative annual cost saving, cost - effectiveness and
st Cost-effectiveness
ratio HCV
Cost-effectiveness
ratio HIV
Cost-benefit
ratio HCV
Cost-benefit
ratio HIV
45 $18,980 $114,884 1.85 1.8
02 $20,400 $124,731 1.7 1.7
08 $25,580 $155,914 1.4 1.4
57 $29,201 $178,188 1.2 1.2
63 $32,006 $194,893 1.1 1.1
12 $34,106 $207,886 1 1
39 $35,784 $218,280 0.96 0.98
13 $30,004 $181,900 1.16 1.17
Table 7 The sensitivity analysis at 25% sharing rate for cumulative annual cost saving, cost - effectiveness and
cost – benefit of SIF in Montreal
Variables Annual cost
of operation
Sharing
rate
# of HIV
averted
# of HCV
averted
HIV cost
saved
HCV cost
saved
Cost-effectiveness
ratio HCV
Cost-effectiveness
ratio HIV
Cost-benefit
ratio HCV
Cost-benefit
ratio HIV
Post SIF $2,182,800 25% 10 64 -$77,250 $66,352 $34,106 $218,280 1.03 1
Two SIF $4,365,600 20% 19 119 -$365,055 -$183,583 $36,686 $229,768 0.96 0.92
Three SIF $6,548,400 15% 23 142 -$1,705,635 -$1,558,094 $46,156 $284,713 0.76 0.74
Four SIF $8,731,200 13% 27 166 -$3,046,215 -$2,897,462 $52,598 $323,377 0.67 0.65
Five SIF $10,914,000 11% 31 190 -$4,386,795 -$4,236,830 $57,442 $352,065 0.61 0.6
Six SIF $13,096,800 9% 35 213 -$5,727,375 -$5,611,341 $61,487 $374,194 0.57 0.56
Seven SIF $15,279,600 7% 39 237 -$7,067,955 -$6,950,709 $71,735 $436,560 0.55 0.54
Average $8,731,200 14% 26 154 -$3,256,770 -$3,319,178 $56,696 $335,815 0.62 0.63
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For simplicity, we assume that the Montreal SIFs would
provide the same injection kits and have similar costs as-
sociated with property rental, staff salaries, and equipment
purchases overall—the same service provision as in the
Vancouver SIF. This is believed to be a conservative esti-
mate because, according to the Canada Mortgage & Hous-
ing Corporation report, rental vacancy rates are higher in
Montreal, resulting in lower commercial rent than
Vancouver [38]. Further, British Columbia has the highest
paid registered nurses and staff in the country [39].
Results and discussion
The model used here [18], predicted the number of new
HIV and HCV cases prevented based on the needle shar-
ing rate. This included the impact of behavioral changes
in injection activities outside of the SIF. The behavioral
change, according to Table 2 and Table 3, was only con-
sidered twice (once for the first SIF and later for the sec-
ond SIF)—this modeling decision is apparent in the
marginal number of new HIV cases averted in Tables 3,
4 and 5. This calculation of behavioral impact is based
on a conservative odds-ratio that falls within the limit
specified by Kerr et al. (2005) [40].Table 8 The cumulative ten years cost - effectiveness and cos
Jacobs et al. [18] model
Variables Annual cost
of operation
# of HIV
averted
# of HCV
averted
Cost-effec
ratio
Post SIF $21,828,000 140 840 $25,9
Two SIF $43,656,000 260 1620 $26,9
Three SIF $65,484,000 320 1950 $33,5
Four SIF $87,312,000 370 2270 $38,4
Five SIF $109,140,000 430 2610 $41,8
Six SIF $130,968,000 480 2940 $44,5
Seven SIF $152,796,000 530 3270 $46,7
Average $87,312,000 360 2210 $39,5As expected, the results presented in Table 2 and Table 3
show that increasing the scope of SIFs through site expan-
sion would result in a decrease of HIV infection cases.
The model predicts: 14–53 fewer HIV cases and 84–327
fewer HCV cases annually, with the marginal range being
much smaller: 5–14 fewer HIV cases and 33–84 fewer
HCV cases annually.
This range disparity, as outlined in Table 2 and Table 3,
translates into substantial differences between the eco-
nomic evaluation of SIFs with respect to the cumulative
versus marginal estimates: the total effect of establishing
SIFs and the effect of establishing each subsequent SIF,
respectively.
For example, according to Table 3, the cumulative an-
nual estimates of new HIV cases averted, translates into
a cost savings for society ranging from $0.764 million
(benefit) for the first SIF to -$4.1 million (loss) for the
seventh SIF. Benefit-cost ratios range from 1.35 to 0.73,
and cost-effectiveness values range from $155,914 to
$288,294 (cost per lifetime treatment). The cumulative
annual estimates of new HCV cases averted translate
into a cumulative cost savings that range from $0.769
million (benefit) for the first SIF to -$3.7 million (loss)
for the seventh SIF. Benefit-cost ratios range from 1.35t – benefit of sif in montreal using the
tiveness
HCV
Cost-effectiveness
ratio HIV
Cost-benefit
ratio HCV
Cost-benefit
ratio HIV
86 $155,914 1.35 1.35
48 $167,908 1.25 1.25
82 $204,637 1.03 1.03
63 $235,978 0.89 0.89
16 $253,814 0.83 0.83
47 $272,850 0.77 0.77
27 $288,294 0.73 0.73
08 $242,533 0.87 0.87
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from $25,986 to $46,727 (cost per lifetime treatment).
In contrast, the marginal estimates of Montreal’s SIF
expansion translate into a much smaller return. This is
particularly true with respect to its benefit-cost and cost-
effectiveness ratios. For instance, the marginal benefit-cost
ratio varies from 1.35 to 0.77 for HIV and 1.35 to 0.76 for
HCV. The marginal cost-effectiveness value for HIV ranges
from $155,914 to $436,560 (cost per life- time treatment).
The HCV marginal cost-effectiveness value ranges from
$25,986 to $66,145 (cost per lifetime treatment).
Furthermore, Table 2 and Table 3 show that both cumu-
lative benefit-cost ratios dwindle after the third SIF. For
example, Table 2 shows that a cost savings of $189,360 is
present for the third SIF (HIV) results, but the further ex-
pansion to four SIFs leads to a $0.940 million loss. A simi-
lar loss due to SIF expansion can be seen for HCV where
a $304,485 cost saving (for the third SIF) changes to a
0.753 million dollar loss (for the fourth SIF). More specif-
ically, the benefit-cost ratio for both HIV and HCV dimin-
ish after the third SIF (from 1.03 to 0.89). Incremental
cost-effectiveness ratios also diminish after the third SIF
with HIV ($204,637 to $235,978 cost per lifetime treat-
ment) and HCV ($33,582 to $38,463 cost per life- time
treatment). This means that they both exceed their cost-
effectiveness ratios of $210, 555 and $35,143 respectively.
Finally, sensitivity analysis was conducted for the models
employed. These employed different initial needle-sharing
rates (see Tables 4, 5, 6 and 7). Similar to [17] and [13],
the current analysis used 20 and 40 per cent initial needle-
sharing rates. Convincingly, the results from both the
baseline and sensitivity analysis in these analyses demon-
strate that the establishment of an SIF program in
Montreal would save tax payers money.
The estimates of 130–140 HIV reductions and 840 HCV
reductions over 10 years (with consideration for growth in
IDUs population) is still cost effective for the first three
SIFs. Results ranged from $155,914 to $204,638 for HIV
(cost per lifetime treatment) and $33,582 to $33,582 for
HCV (cost per lifetime treatment). Further, the benefit-cost
ratio is above 1 for both HIV and HCV for the first three
SIF over 10 years of establishment (see Table 8).Conclusions
The current analysis set out to assess whether establishing
a SIF in Montreal would have a (net) positive fiscal impact
on society. In particular, it assessed whether or not this
policy initiative would save public health care funds by
averting new HIV and HCV infections. Moreover, upon
completion of the economic evaluation for the proposed
SIF in Montreal, the optimal number of SIFs was assessed
based on marginal cost-saving, cost-effectiveness, and
benefit-to-cost ratios.The results presented here suggest that establishing SIFs
in Montreal will benefit the publically funded health care
system. Further, the implementation of additional SIFs
would serve a as a fiscally responsible course of action. It
should be noted that although expansion beyond the third
SIF location may not provide the same economic return, it
may still be considered cost-effective (even if it is not cost
saving) given that the analyses used highly conservative es-
timates in the baseline calculations. For example, the poten-
tial for cost-savings with respect to cellulitis, subcutaneous
abscesses, endocarditis, and incidence of soft-tissue infec-
tions averted were not considered in the calculations.
In addition, for incidents of HIV and HCV, the lower
bound estimates were considered. For example, when con-
sidering HIV, the current analyses omitted the parameters
found to be specified in the HAART program and instead,
relied on the lower cost estimates for HIV and HCV.
Hence, only at very high levels of coverage is there a
diminishing return in the number of new HIV and HCV
infections averted for each dollar invested. Moreover, even
if the calculations predicted that the expansion beyond the
fourth SIF may not be economically desirable (because the
benefit-to-cost ratio or cost-effectiveness ratios are not
favourable), they could become so in the future because
other studies have shown that future benefits will out-
weigh the start-up costs [41]. As a result, the current
model most certainly underestimated the benefits.
While some researchers remain sceptical with respect to
the economic rationale for ancillary SIFs [16,30], it should
be noted that other models used in recent research have
consistently demonstrated the benefits of such expansion
[13]. The main difference between the current study’s
findings and those in [16,30] is the consideration of behav-
ioral change. Behavioral change has been shown to be an
important aspect of the result not only in this costing
study, but other studies as well [13,17]. The conditions
under which the establishment of a SIF will be economic-
ally efficient and cost-saving stem from two sources; one
being the provision of clean injecting equipment, and the
other being the easier accessibility of services that translate
into transformative changes in IDUs behavior (e.g., injec-
tion behavior outside Insite becomes less risky).
In sum, establishing SIFs in Montreal has been shown
to be cost-saving and the results presented here fall
within the range of existing cost-effectiveness/cost-bene-
fit studies despite the variation in methodologies
employed. Specifically, this paper has shown that the
number of new HIV and HCV infections averted, and
the associated cost-savings, are more than enough
to cover the cost of operating more than one SIF in
Montreal. Therefore, if one accepts the scientific evi-
dence behind the behavioral change in the IDU popula-
tion, there is a substantial case for establishing a SIF in
Montreal. This should serve as an encouraging result for
Jozaghi et al. Substance Abuse Treatment, Prevention, and Policy 2013, 8:25 Page 8 of 8
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solutions to serious health care problems in a climate of
scarce public resources.
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